pubmed.ncbi.nlm.nih.gov

Hemophilic Arthropathy of the Knee and Its Association with Reduced Muscle Strength and Activation and the Pressure Pain Threshold: A Case-Control Study - PubMed

  • ️Sun Jan 01 2023

Hemophilic Arthropathy of the Knee and Its Association with Reduced Muscle Strength and Activation and the Pressure Pain Threshold: A Case-Control Study

Mar Villalón-González et al. J Clin Med. 2023.

Abstract

(1) Background: Hemophilia is characterized by recurrent hemarthrosis leading to degenerative arthropathy. The aim was to evaluate the differences in muscle strength and activity and the pressure pain threshold between patients with knee arthropathy and their healthy peers; (2) Methods: A case-control study in which 23 adult patients with knee arthropathy and 24 healthy peers matched in terms of characteristics were recruited. The study variables were quadriceps muscle strength, muscle activation and the pressure pain threshold; (3) Results: There were significant differences between the two groups in quadriceps strength on the dominant (CI95%: 64.69, 129.2) and non-dominant (CI95%: 29.95, 93.55) sides and in the pressure pain threshold on the dominant (CI95%: 3.30, 43.54) and non-dominant (CI95%: 3.09, 45.25) sides. There were differences in neuromuscular fatigue on the non-dominant side in the vastus medialis (CI95%: 8.72, 21.51), vastus lateralis (CI95%: 4.84, 21.66) and rectus femoris (CI95%: 6.48, 24.95) muscles; (4) Conclusions: Muscle strength and the pressure pain threshold are lower in patients with hemophilia. Quadriceps muscle activation in patients with hemophilic knee arthropathy does not in any way differ from activation in healthy subjects. However, muscle fatigue is greater in patients with knee arthropathy. Strength training in patients with hemophilia should focus on the activation of the vastus medialis and lateralis muscles.

Keywords: electromyography; hemophilia; knee arthropathy; pressure pain threshold; quadriceps strength.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Similar articles

References

    1. Srivastava A., Brewer A.K., Mauser-Bunschoten E.P., Key N.S., Kitchen S., Llinas A., Ludlam C.A., Mahlangu J.N., Mulder K., Poon M.C., et al. Guidelines for the Management of Hemophilia. Haemophilia. 2013;19:e1–e47. doi: 10.1111/j.1365-2516.2012.02909.x. - DOI - PubMed
    1. Gualtierotti R., Solimeno L.P., Peyvandi F. Hemophilic Arthropathy: Current Knowledge and Future Perspectives. J. Thromb. Haemost. 2021;19:2112–2121. doi: 10.1111/jth.15444. - DOI - PMC - PubMed
    1. Shetty S., Bansal S., Kshirsagar S., Rangarajan S., Hajirnis K., Phadke V. Low-Dose Prophylaxis and Its Impact on the Health of Haemophilia Patients. Vox Sang. 2022;117:900–912. doi: 10.1111/vox.13278. - DOI - PubMed
    1. Tomeo F., Mariz S., Brunetta A.L., Stoyanova-Beninska V., Penttila K., Magrelli A. Haemophilia, State of the Art and New Therapeutic Opportunities, a Regulatory Perspective. Br. J. Clin. Pharmacol. 2021;87:4183–4196. doi: 10.1111/bcp.14838. - DOI - PMC - PubMed
    1. Berntorp E., Hermans C., Solms A., Poulsen L., Mancuso M.E. Optimising Prophylaxis in Haemophilia A: The Ups and Downs of Treatment. Blood Rev. 2021;50:100852. doi: 10.1016/j.blre.2021.100852. - DOI - PubMed

LinkOut - more resources